Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,963.00
Ask: 1,965.00
Change: -36.00 (-1.81%)
Spread: 2.00 (0.102%)
Open: 2,004.00
High: 2,004.00
Low: 1,958.00
Prev. Close: 1,994.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Potential strike on Syria worries investors early on

Wed, 04th Sep 2013 08:32

Stocks declined on Wednesday morning on concerns over an imminent Western military intervention in Syria, with investors also choosing to scale back positions ahead of a number of 'risk events' later on in the week.The Senate Foreign Relations Committee last night gave the green light on a US attack on Syria, saying that the use of force "reflects the will and concerns of Democrats and Republicans alike".The backing of the Committee "reminded investors that the potential for war is still lurking", according to Financial Trader Shavaz Dhalla from Spreadex.This comes ahead of the crucial vote in Congress next week on President Barack Obama's call for action against the Bashar al-Assad regime which he claims is responsible for the deadly chemical weapons attack against the Syrian people in August.Dhalla said: "Many now believe that if a strike is approved, this would likely occur in a much smaller scale and involve a fewer number of countries than initially expected. Despite this, the possible legal repercussions from Syria's allies, which include China and Russia, if the strike does happen without UN approval is still troubling investors."Traders will also be cautious today ahead of three central-bank meetings tomorrow from the Bank of Japan, Bank of England and the European Central Bank. These will be followed by the all-important US jobs report on Friday which will be a large factor in the Federal Reserve's decision on whether or not to adjust current stimulus measures later this month.FTSE 100: Airline stocks sink after Ryanair profit warningAirline peers easyJet and IAG were flying lower this morning after a gloomy outlook by Ryanair on the back of the hot weather in Northern Europe over the summer. The company scaled back its full-year profit guidance after worse-than-expected bookings but said that it could even fail to meet these forecasts if fares and yields continue to weaken over the coming winter.Hargreaves Lansdown fell despite reporting record annual figures this morning. Full-year pre-tax profit rose 28% to £195.2m as the financial services company took on more clients and increased assets under administration by 38% rise in AuA to £36.4bn. Weighing on the price this morning could be Morgan Stanley's downgrade of the 'Diversified Financial' sector to 'neutral'.TUI Travel, Resolution and BHP Billiton were also heavy fallers this morning after going ex-dividend, meaning that from today new investors won't be able to get their hands on their latest dividend payments. Others that went ex-dividend on the blue-chip index include Admiral, Aggreko, ARM Holdings, IMI, Land Securities, Serco Group and Shire.Chemicals group Croda International also went ex-div today but was trading higher after Exane BNP Paribas upgraded its rating on the stock to 'outperform'.British Land fell after saying it is set to purchase 50% of 430,000 square-foot SouthGate retail space in Bath by paying current owner Multi Southgate £101m.FTSE 250: Phoenix lower after going ex-divClosed life and pension fund consolidator Phoenix was the worst performer this morning after going ex-dividend. A host of others were also trading without the rights to their latest payouts, including 888 Holdings, Betfair, Elementis, esure, Greggs, Hikma Pharmaceuticals, Jardine Lloyd Thompson, Michael Page International, Micro Focus International, National Express Group, Polymetal International, Regus, SEGRO and Xaar.Ashtead Group rose after the equipment rental company booked a 24% increase in first-quarter revenue amid strong demand and a tight control on costs. It now expects a full-year result ahead of previous expectations. Kenmare Resources was higher after Goldman raised its recommendation to 'conviction buy', while Salamander Energy was boosted by a Morgan Stanley upgrade to 'equalweight'.FTSE 100 - RisersVodafone Group (VOD) 206.30p +1.88%Fresnillo (FRES) 1,295.00p +1.33%Experian (EXPN) 1,147.00p +1.15%HSBC Holdings (HSBA) 691.50p +0.57%BG Group (BG.) 1,252.50p +0.44%Shire Plc (SHP) 2,396.00p +0.38%Petrofac Ltd. (PFC) 1,401.00p +0.36%Serco Group (SRP) 551.50p +0.27%Johnson Matthey (JMAT) 2,924.00p +0.24%WPP (WPP) 1,236.00p +0.24%FTSE 100 - FallerseasyJet (EZJ) 1,190.00p -7.03%International Consolidated Airlines Group SA (CDI) (IAG) 282.60p -4.11%Resolution Ltd. (RSL) 312.20p -4.06%TUI Travel (TT.) 333.50p -3.53%Hargreaves Lansdown (HL.) 998.00p -3.20%BHP Billiton (BLT) 1,887.50p -2.51%William Hill (WMH) 405.90p -2.17%Carnival (CCL) 2,339.00p -1.93%Persimmon (PSN) 1,121.00p -1.84%Associated British Foods (ABF) 1,867.00p -1.79%FTSE 250 - RisersBumi (BUMI) 220.50p +5.65%Kenmare Resources (KMR) 28.30p +4.04%UK Commercial Property Trust (UKCM) 76.45p +1.80%Salamander Energy (SMDR) 131.40p +1.78%JPMorgan Indian Inv Trust (JII) 294.60p +1.73%Fisher (James) & Sons (FSJ) 1,109.00p +1.46%Big Yellow Group (BYG) 414.40p +1.44%F&C Commercial Property Trust Ltd. (FCPT) 115.50p +1.32%Daejan Holdings (DJAN) 3,818.00p +1.14%Dixons Retail (DXNS) 44.67p +1.11%FTSE 250 - FallersPhoenix Group Holdings (DI) (PHNX) 713.50p -5.50%Thomas Cook Group (TCG) 137.00p -3.93%Micro Focus International (MCRO) 741.50p -3.76%Barratt Developments (BDEV) 305.20p -3.11%Menzies(John) (MNZS) 770.00p -3.02%Mitchells & Butlers (MAB) 434.00p -2.95%Taylor Wimpey (TW.) 100.10p -2.91%Carillion (CLLN) 283.80p -2.64%Ashtead Group (AHT) 669.50p -2.62%Amlin (AML) 380.30p -2.46%BC
More News
9 Feb 2022 09:48

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Read more
3 Feb 2022 09:12

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets

Read more
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more
4 Nov 2021 09:03

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

Read more
4 Nov 2021 07:58

Hikma reports solid trading in year to date

(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.

Read more
1 Nov 2021 13:52

Citi sees room for upside surprise on sales at Hikma Pharmaceuticals

(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.

Read more
28 Oct 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.